Table 4 Exploratory responder analysis for efficacy population in adolescent (N  =  146) and adult (N = 153) trials

From: Two single arm trials of AKL-T01, a digital therapeutic for adolescents and adults with ADHD

Study

Parameter

n/N (%)

Adolescent

TOVA-ACS: 1.4-point improvement from baseline to day 28

89/146 (61.0%)

TOVA-ACS: Score at exit visit ≥ 0

36/146 (24.7%)

ADHD RS-5 Total Score: ≥ 30% improvement from baseline to day 28

39/144 (27.1%)

Adult

TOVA-ACS: 1.4-point improvement from baseline to day 42

127/153 (83.0%)

TOVA-ACS: Score at exit visit ≥ 0

56/153 (36.6%)

ADHD RS-IV Total Score: ≥ 30% improvement from baseline to day 42

50/153 (32.7%)

AAQoL: ≥ 8 point improvement from baseline to day 42

70/153 (45.8%)

  1. ADHD RS-5 Attention Deficit Hyperactivity Disorder Rating Scale-5, TOVA-ACS Test of Variables of Attention-Attention Comparison Score, ADHD RS-IV Attention Deficit Hyperactivity Disorder Rating Scale-IV.
Back to article page